MarketMindUS Markets Open
AI-assisted · Not financial adviceNot adviceAI-assisted · Not financial advice.
Retail sentiment is mixed on IBRX, focusing on FDA implications, while news reports a class action lawsuit. Investors should consider the potential legal risks alongside growth opportunities.
ImmunityBio faces class action lawsuit
Target: $14 avg (+64% upside)
5 Buy · 0 Hold · 0 Sell
Based on curated news sources (not retail comments)
Over the last 7 days: ImmunityBio has strong revenue growth signals and a promising transition to a broader platform, but legal challenges and FDA scrutiny create significant downside risks.